June 2013
Volume 54, Issue 15
Free
ARVO Annual Meeting Abstract  |   June 2013
Role of the Krebs Cycle metabolite α-ketoglutarate and its receptor, GPR99, in retinal angiogenesis
Author Affiliations & Notes
  • Francois Duhamel
    Pharmacology, Ste-Justine Hospital Research Center, Montreal, QC, Canada
  • Karine Zaniolo
    Pharmacology, Ste-Justine Hospital Research Center, Montreal, QC, Canada
  • Houda Tahiri
    Pharmacology, Ste-Justine Hospital Research Center, Montreal, QC, Canada
  • Sylvain Chemtob
    Pharmacology, Ste-Justine Hospital Research Center, Montreal, QC, Canada
  • Footnotes
    Commercial Relationships Francois Duhamel, None; Karine Zaniolo, None; Houda Tahiri, None; Sylvain Chemtob, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2013, Vol.54, 605. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Francois Duhamel, Karine Zaniolo, Houda Tahiri, Sylvain Chemtob; Role of the Krebs Cycle metabolite α-ketoglutarate and its receptor, GPR99, in retinal angiogenesis. Invest. Ophthalmol. Vis. Sci. 2013;54(15):605.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: Retinopathy of prematurity (ROP), a major cause of blindness in developed countries, occurs in two phases: the cessation of normal eye development after birth and a subsequent abnormal and exaggerated vessel growth. Peripheral hypoxia occurs after the first phase in premature eye and induces production of many growth factors implicated in this second destructive neovascularization phase. Our laboratory has previously demonstrated the role of succinate/GPR91 in the modulation of retinal vessel growth. Here, we investigated the role of α-ketoglutarate and its cognate receptor GPR99 in retinal angiogenesis.

Methods: Effects of α-ketoglutarate on developmental retinal vascularisation were assessed following intravitreal injection of Sprague-Dawley rat pups in development. Moreover, the effects of a siGPR99 knockdown following intravitreal injection were investigated in the neovascular phase of ROP. Endogenous expression of retinal GPR99 was assessed by immunohistochemistry on retina cuts and Western blots analysis of different cell lines while expression of pro-angiogenic factors was assessed by PCR analysis. The ability of α-ketoglutarate to promote vessel sprouting was determined by aortic rings cultures.

Results: α-ketoglutarate significantly enhanced developmental vascular densities at different time points. Neovascularization was blocked by a siGPR99 and allowed normal vessel growth in ROP. Moreover, GPR99 was robustly expressed in RGCs as confirmed by co-labeling with neuron markers and, in vitro, mainly in neuronal cells. Conditioned media from α-ketoglutarate stimulated-neurons induced aortic rings sprouting, in correlation with an up-regulation of pro-angiogenic factors expression.

Conclusions: Our results disclose a pro-angiogenic role for α-ketoglutarate and its receptor, GPR99, providing increasing supports for the involvement of metabolite signalling in ischemic conditions.

Keywords: 706 retinopathy of prematurity • 531 ganglion cells • 674 receptors  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×